

Usefulness of a multiplex PCR for the rapid identification of *Candida glabrata* species complex in Mexican clinical isolates

María del Rocío Reyes-Montes^{1*}, Gustavo Acosta-Altamirano^{2*}, Esperanza Duarte-Escalante¹, Eduardo García Salazar², Erick Martínez-Herrera², Roberto Arenas³, Gloria González⁴, María Guadalupe Frías-De-León^{1,2}

ABSTRACT

Candida glabrata complex includes three species identified through molecular biology methods: *C. glabrata sensu stricto*, *C. nivariensis* and *C. bracarensis*. In Mexico, the phenotypic methods are still used in the diagnosis; therefore, the presence of *C. nivariensis* and *C. bracarensis* among clinical isolates is still unknown. The aim of this study was to evaluate the utility of a multiplex PCR for the identification of the *C. glabrata* species complex. DNA samples from 92 clinical isolates that were previously identified through phenotypic characteristics as *C. glabrata* were amplified by four oligonucleotides (UNI-5.8S, GLA-f, BRA-f, and NIV-f) that generate amplicons of 397, 293 and 223-bp corresponding to *C. glabrata sensu stricto*, *C. nivariensis*, and *C. bracarensis*, respectively. The amplicon sequences were used to perform a phylogenetic analysis through the Maximum Likelihood method (MEGA6), including strains and reference sequences of species belonging to *C. glabrata* complex. In addition, recombination and linkage disequilibrium were estimated (DnaSP version 5.0) for *C. glabrata sensu stricto* isolates. Eighty-eight isolates generated a 397-bp fragment and only in one isolate a 223-bp amplicon was observed. In the phylogenetic tree, the sequences of 397-bp were grouped with *C. glabrata* reference sequences, and the sequence of 223-bp was grouped with *C. bracarensis* reference sequences, corroborating the PCR identification. The number of recombination events for the isolates of *C. glabrata sensu stricto* was zero, suggesting a clonal population structure. Three isolates that did not amplify any of the expected fragments were identified as *Saccharomyces cerevisiae* through the sequencing of the D1/D2 domain region within the 28S rDNA gene. The multiplex PCR is a fast, cost-effective and reliable tool that can be used in clinical laboratories to identify *C. glabrata* complex species.

KEYWORDS: *Candida glabrata* complex. *Candida bracarensis*. *Candida nivariensis*. Multiplex PCR. Candidiasis. Mexico.

INTRODUCTION

Candidiasis is the most frequent opportunistic mycosis in the world. *Candida albicans* is the main agent of candidiasis, but *Candida glabrata* has emerged as the second most important agent of invasive candidiasis in Central and Northern Europe and in the United States; however, in some Asian, African and Latin American countries, it ranks third or fourth place¹. In Mexico, the etiologic diversity of invasive candidiasis is similar to that reported in other countries, where *C. albicans* is followed by the *C. glabrata* complex, *C. krusei*, *C. tropicalis* and the *C. parapsilosis* complex causes more than 90% of cases, whereas

¹Universidad Nacional Autónoma de México, Facultad de Medicina, Departamento de Microbiología y Parasitología, Ciudad de México, México

²Hospital Regional de Alta Especialidad de Ixtapaluca, Unidad de Investigación, Ixtapaluca, México

³Hospital General "Dr. Manuel Gea González, Sección de Micología, Ciudad de México, México

⁴Universidad Autónoma de Nuevo León, Facultad de Medicina, Departamento de Microbiología, Monterrey, México

*Both authors contributed equally to this work

Correspondence to: María Guadalupe Frías-De-León

Hospital Regional de Alta Especialidad de Ixtapaluca, Unidad de Investigación, Carretera Federal México – Puebla Km 34.5, Pueblo de Zoquiapan, 56530, Ixtapaluca, Estado de México, México
Tel: +55 52 5972-9800

E-mail: magpefrías@gmail.com

Received: 14 March 2019

Accepted: 25 June 2019

C. guilliermondii, *C. lipolytica*, *C. famata*, *C. zeylanoides*, *C. utilis*, *C. rugosa* and *C. boidinii* are infrequent agents^{2,3}. The clinical relevance of the emergence of the *C. glabrata* complex as a frequent pathogen lies in the fact that this complex includes three species: *C. glabrata sensu stricto*, *Candida bracarensis* and *Candida nivariensis*⁴⁻⁶, which can cause similar clinical manifestations although they are genetically diverse and differ regarding virulence factors and susceptibility to antifungals^{3,7-10}. Therefore, the correct identification of the species of *C. glabrata* complex can lead to the appropriate choice of antifungal therapy. The identification of these species is not easy using phenotypic methods; thus, molecular tests have been developed¹¹⁻¹⁸. Among these tests, amplification and sequencing of the internal transcribed spacer (ITS) and the D1/D2 domain of the large subunit rRNA gene regions stand out^{4,18-22}, as well as the amplification of gene fragments with specific oligonucleotides that allow an easy differentiation of species based on the amplicon molecular weight^{23,24}. However, in many clinical laboratories, particularly in Latin America, molecular tests are still not used due to their costs as well as their methodological complexities, which has led to the erroneous identification of *C. nivariensis* and *C. bracarensis* as *C. glabrata* among clinical isolates.

The aim of this work was to evaluate the usefulness of a multiplex PCR assay (targeting the ITS1 region and the 5.8S ribosomal RNA gene) for the identification of the species of *C. glabrata complex* and to confirm the multiplex PCR results through a phylogenetic analysis.

MATERIAL AND METHODS

Clinical isolates and culture conditions

Ninety-two clinical isolates of the *C. glabrata* complex (Cgl-1 to Cgl-92) were included in this study. The isolates were obtained from vaginal exudates, blood samples, biopsies, semen samples, abscesses, peritoneal dialysis fluid and catheter tips collected in two tertiary hospitals (1 and 2) located in Mexico City, during the period of January-June 2017. Sixty-five isolates (Cgl-1 to Cgl-65) were obtained from hospital 1, and twenty-seven (Cgl-66 to Cgl-92) from hospital 2. Each isolate was recovered from a single patient. All isolates were previously identified by the automated system VITEK® 2 Compact (bioMérieux, France) as *C. glabrata*, with 93-98% probability of identification. *C. glabrata* ATCC® 2001™, *C. bracarensis* Cb-1 and ExV75 were included as reference strains. The Cb-1 strain was identified by proteomics through the MALDI-TOF MS spectrometry (score value 2.1), and was kindly provided by *Dr. Rosa Areli Martínez Gamboa*,

Instituto Nacional de Ciencias Médicas y de la Nutrición “Salvador Zubirán”, Mexico City. The ExV75 strain was identified by sequencing the ITS region and reported by Trevino-Rangel *et al.*²⁵.

Isolates were grown in Sabouraud agar containing chloramphenicol, at 28 °C. Yeasts were kept at room temperature in a saline solution (NaCl 0.8%).

Extraction of genomic DNA

Yeasts were cultured in YEPG medium (1% yeast extract, 2% peptone, 2% glucose), cells were harvested by centrifugation and washed three times with sterile distilled water. DNA from the yeasts was extracted and purified using the Yeast DNA Preparation kit (Jena Bioscience, GE), following the manufacturer's instructions. DNA samples were stored at 4 °C.

PCR

DNA from the yeasts was amplified through multiplex PCR, using the primers designed by Romeo *et al.*²³. The reaction mixture (25 µL) contained: 1X PCR buffer, 100 pmol/µL of each oligonucleotide (UNI-5.8S 5'-ACCAGAGGGCGCAATGTG-3', GLA-f 5'-CGGTTG GTGGGTGTTCTGC-3', BRA-f 5'-GGGACGGTAAG TCTCCCG-3', NIV-f 5'-AGGGAGGAGTTTGTATCT TTCAAC-3') (Sigma-Aldrich, USA), 200 µM of each dNTP (Jena Bioscience), 2.5 mM MgCl₂, 1 U *Taq* DNA polymerase (Jena Bioscience), and 10 ng of genomic DNA. As a negative control, sterile Milli-Q® water (Merck Millipore, USA) was included. Reactions were carried out in a thermocycler T100™ (Bio-Rad, Laboratories, Inc., USA).

The PCR cycles parameters were as follows: preheating at 95 °C for 5 min; then 34 cycles of 94 °C for 30 s, 60 °C for 40 s and 72 °C for 50 s, and a final extension at 72 °C for 10 min. Amplicons were analyzed by electrophoresis in 1.7% agarose gels (Pronadisa, ES) stained with 3X GelRed™ (Biotium, USA). The electrophoresis was performed in TBE (45 mM Tris-Base, 45 mM boric acid, 1 mM EDTA, pH 8.3) at 100 V for approximately 45 min. A 100-bp DNA molecular size marker was used (Jena Bioscience). Amplified DNA fragments were visualized in a UV transilluminator and then documented (Gel Doc™ EZ Documentation System, Bio-Rad Laboratories). The expected molecular weights of the amplification products were 397, 293 and 223-bp for *C. glabrata sensu stricto*, *C. nivariensis*, and *C. bracarensis*, respectively. All amplicons were sequenced in both directions at the Genomic Services Unit in LANGEBIO (CINVESTAV, Mexico).

Sequences analysis

All DNA sequences from the isolates were edited with the program BioEdit ver. 7.2.5.²⁶. Subsequently, they were analyzed with the BLAST (Basic Local Alignment Search Tool) program²⁷ available at www.blast.ncbi.nlm.nih.gov/blast.cgi to verify the identity, similarity and “e-value” between sequences.

Phylogenetic analysis

All sequences were aligned using the Muscle algorithm within MEGA6 with default options²⁸. The statistical method of Maximum Likelihood was used, a phylogeny test that includes the bootstrap method with 1,000 pseudo replicates; then, replicates were analyzed with the MEGA6 program²⁸. As a reference, sequences of *C. glabrata* complex deposited in GenBank (*C. bracarensis* AY589573.2 and MF187327.1, *C. nivariensis* AY620957.1, *C. glabrata* AY198398.1)²³ were included for comparisons. A sequence of *C. albicans* (JN882343.1) was used as an outgroup.

Recombination detection and linkage disequilibrium

The recombination and linkage disequilibrium was calculated (DnaSP version 5.0)²⁹. The ZZ statistic³⁰ was used to verify the effect of intragenic recombination on nucleotide variation by analyzing the level of linkage disequilibrium.

RESULTS

PCR

From the total of 92 isolates, 88 amplified a 397-bp fragment, compatible with *C. glabrata sensu stricto*; whereas only one (Cgl-60), showed a 223-bp amplicon, suggestive of *C. bracarensis*. The reference strains (ATCC[®] 2001[™], Cb-1 and ExV75) amplified the expected fragments (Figure 1). None of the isolates amplified a 293-bp fragment, corresponding to *C. nivariensis*.

Sequence analysis

The 397-bp sequences (accession no: MK583352 – MK583407 and MK583409 – MK583440) analyzed by BLAST revealed an identity and similarity of 100% (“e-value” equal to zero) with partial sequences of the ITS1-5.8S-ITS2 region from *C. glabrata* (gb|MK026347.1, gb|MH699024.1, gb|LC389240.1, gb|LS398123.1, gb|MG599239.1, gb|MH016268.1, gb|MF033154.1, gb|LC317501.1).




Figure 1 - Electrophoresis of the multiplex-PCR for the identification of clinical isolates of the *Candida glabrata* complex. M: molecular weight marker 100-bp; lane 1: *Candida glabrata* ATCC[®] 2001[™] strain; lane 2: *Candida bracarensis* Cb-1 strain; lane 3: *Candida bracarensis* ExV75 strain; lane 4: isolate Cgl-59; lane 5: isolate Cgl-61; lane 6: isolate Cgl-63; lane 7: isolate Cgl-90; lane 8: isolate Cgl-92; lane 9: negative control (sterile water instead of DNA).

The 223-pb sequence analyzed by BLAST (from the isolate Cgl-60, accession no: MK583408) showed 100% identity and similarity (“e-value” equal to $2e^{-111}$) with partial sequences of the ITS1-5.8S-ITS2 region from *C. bracarensis* (gb|JN882340.1, gb|GU199439.1, gb|GU199438.1, gb|NR136973.1, gb|MF084287.1, gb|MF187327.1, gb|KP674715.1, gb|KP131680.1).

Three isolates (Cgl-2, Cgl-28, and Cgl-32) showed no amplification even after the testing of different DNA concentrations. Therefore, a region of the D1/D2 domain of the 28S rDNA gene was amplified and sequenced with the universal oligonucleotides NL1 (5'-GCATATCAATAAGCGGAGGAAAAG-3') and NL4 (5'-GGTCCGTGTTTCAAGACGG-3')³¹. A 588-bp amplicon was obtained from the three isolates. The BLAST analysis of these sequences showed 100% identity and similarity with the sequence of *Saccharomyces cerevisiae* gb|LC334458.1, corresponding to the 28S ribosomal RNA region.

Phylogenetic analysis

The phylogenetic tree showed three groups supported by a 99% bootstrap: group I included all isolates that amplified the 397-bp fragment and reference sequences of *C. glabrata* distributed in three subgroups. The subgroup Ia included the majority of isolates from hospital 1; the subgroup Ib included most isolates from hospital 2 and the subgroup Ic included three isolates from hospital 1. The group II included the reference sequence (AY620957.1) of *C. nivariensis* and group III included that single isolate (Cgl-60), as well as the reference sequences (MF187327.1, AY589573.2, Cb-1 and ExV75) corresponding to *C. bracariensis* (Figure 2).

because the VITEK system® 2 Compact is not the most suitable method for the identification of *C. glabrata*^{36,41}. The phylogeny constructed with the sequences from the isolates confirmed the identification by PCR; the clustering corroborated that 88 isolates corresponded to *C. glabrata sensu stricto*, and one to *C. bracarensis*. Furthermore, the data obtained from the linkage disequilibrium analysis and the recombination of *C. glabrata* isolates from hospitals 1 and 2 suggested the existence of a clonal population structure as shown by Lott *et al.*⁴². These results indicate the permanence and dissemination of one clone, which could represent an advantage since some researchers have speculated that the predominance of one genotype may have selective ecological benefits such as the decrease of virulent strains and of resistance to antifungal agents⁴³.

Based on the results obtained in this study, we recommend the multiplex PCR proposed by Romeo *et al.*²³ as a cost-effective, simple, fast and reliable tool for the identification of clinical isolates of the *C. glabrata* species complex. Although it is important to note that the cultivation of yeasts is still necessary to determine the susceptibility to antifungals, the combination of multiplex PCR and culture will contribute to a specific diagnosis, as well as to the understanding of the epidemiology and pathogenic relevance of these yeasts.

CONCLUSION

The multiplex PCR with oligonucleotides UNI-5.8S, GLA-f, BRA-f and NIV-f is an accessible, reliable and fast tool that can be used routinely in clinical laboratories to identify the species of the *C. glabrata* complex.

CONFLICT OF INTERESTS

The authors have declared that no competing interests exist.

ACKNOWLEDGMENTS

To Dr. *Rosa Areli Martínez Gamboa*, for the donation of the Cb-1 strain. The authors thank Mariana Pardo Ceballos for her editorial assistance.

REFERENCES

- Quindós G. Epidemiology of candidaemia and invasive candidiasis. A changing face. *Rev Iberoam Micol.* 2014;31:42-8.
- Chapman B, Slavin M, Marriott D, Halliday C, Kidd S, Arthur I, et al. Changing epidemiology of candidemia in Australia. *J Antimicrob Chemother.* 2017;72:1103-8.
- Reyes-Montes MR, Duarte-Escalante E, Martínez-Herrera E, Acosta-Altamirano G, Frías-De León MG. Current status of the etiology of candidiasis in Mexico. *Rev Iberoam Micol.* 2017;34:203-10.
- Alcoba-Flórez J, Méndez-Álvarez S, Cano J, Guarro J, Pérez-Roth E, del Pilar Arévalo M. Phenotypic and molecular characterization of *Candida nivariensis* sp. nov., a possible new opportunistic fungus. *J Clin Microbiol.* 2005;43:4107-11.
- Correia A, Sampaio P, James S, Pais C. *Candida bracarensis* sp. nov., a novel anamorphic yeast species phenotypically similar to *Candida glabrata*. *Int J Syst Evol Microbiol.* 2006;56:313-7.
- Gabaldón T, Martin T, Marcet-Houben M, Durrens P, Bolotin-Fukuhara M, Lespinet O, et al. Comparative genomics of emerging pathogens in the *Candida glabrata* clade. *BMC Genomics.* 2013;14:623.
- Bishop JA, Chase N, Magill SS, Kurtzman CP, Fiandaca MJ, Merz WG. *Candida bracarensis* detected among isolates of *Candida glabrata* by peptide nucleic acid fluorescence in situ hybridization: susceptibility data and documentation of presumed infection. *J Clin Microbiol.* 2008;46:443-6.
- Borman AM, Petch R, Linton CJ, Palmer MD, Bridge PD, Johnson EM. *Candida nivariensis*, an emerging pathogenic fungus with multidrug resistance to antifungal agents. *J Clin Microbiol.* 2008;46:933-8.
- Fujita S, Senda Y, Okusi T, Ota Y, Takada H, Yamada K, et al. Catheter-related fungemia due to fluconazole-resistant *Candida nivariensis*. *J Clin Microbiol.* 2007;45:3459-61.
- Figueiredo-Carvalho MH, Ramos LS, Barbedo LS, Chaves AL, Muramoto IA, Santos AL, et al. First description of *Candida nivariensis* in Brazil: antifungal susceptibility profile and potential virulence attributes. *Mem Inst Oswaldo Cruz.* 2016;111:51-8.
- Page BT, Shields CE, Merz WG, Kurtzman CP. Rapid identification of ascomycetous yeasts from clinical specimens by a molecular method based on flow cytometry and comparison with identifications from phenotypic assays. *J Clin Microbiol.* 2006;44:3167-71.
- Bader O, Weig M, Taverne-Ghadwal L, Lugert R, Gross U, Kuhns M. Improved clinical laboratory identification of human pathogenic yeasts by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. *Clin Microbiol Infect.* 2011;17:1359-65.
- Pinto A, Halliday C, Zahra M, van Hal S, Olma T, Maszewska K, et al. Matrix-assisted laser desorption ionization-time of flight mass spectrometry identification of yeasts is contingent on robust reference spectra. *PLoS One.* 2011;6:e25712.
- Telleria O, Ezpeleta G, Herrero O, Miranda-Zapico I, Quindós G, Cisterna R. Validation of the PCR-dHPLC method for rapid identification of *Candida glabrata* phylogenetically related species in different biological matrices. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2012;893-894:150-6.

15. Decat E, Van Mechelen E, Saerens B, Vermeulen SJ, Boekhout T, De Blaiser S, et al. Rapid and accurate identification of isolates of *Candida* species by melting peak and melting curve analysis of the internally transcribed spacer region 2 fragment (ITS2-MCA). *Res Microbiol.* 2013;164:110-7.
16. Enache-Angoulvant A, Guitard J, Grenouillet F, Martin T, Durrens P, Fairhead C, et al. Rapid discrimination between *Candida glabrata*, *Candida nivariensis*, and *Candida bracarensis* by use of a singleplex PCR. *J Clin Microbiol.* 2011;49:3375-9.
17. Ghosh AK, Paul S, Sood P, Rudramurthy SM, Rajbanshi A, Jillwin TJ, et al. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry for the rapid identification of yeasts causing bloodstream infections. *Clin Microbiol Infect.* 2015;21:372-8.
18. Dudiuk C, Morales-López SE, Podesta V, Macedo D, Leonardelli F, Vitale RG, et al. Multiplex PCR designed to differentiate species within the *Candida glabrata* complex. *Rev Iberoam Micol.* 2017;34:43-5.
19. Alcoba-Flórez J, Arévalo MP, González-Paredes FJ, Cano J, Guarro J, Pérez-Roth E, et al. PCR protocol for specific identification of *Candida nivariensis*, a recently described pathogenic yeast. *J Clin Microbiol.* 2005;43:6194-6.
20. Cornet M, Sendid B, Fradin C, Gaillardin C, Poulain D, Nguyen HV. Molecular identification of closely related *Candida* species using two ribosomal intergenic spacer fingerprinting methods. *J Mol Diagn.* 2011;13:12-22.
21. Mirhendi H, Bruun B, Schonheyder HC, Christensen JJ, Fuursted K, Gahrn-Hansen B, et al. Differentiation of *Candida glabrata*, *C. nivariensis* and *C. bracarensis* based on fragment length polymorphism of ITS1 and ITS2 and restriction fragment length polymorphism of ITS and D1/D2 regions in rDNA. *Eur J Clin Microbiol Infect Dis.* 2011;30:1409-16.
22. Gorton RL, Jones GL, Kibbler CC, Collier S. *Candida nivariensis* isolated from a renal transplant patient with persistent candiduria: molecular identification using ITS PCR and MALDI-TOF. *Med Mycol Case Rep.* 2013;2:156-8.
23. Romeo O, Scordino F, Pernice I, Lo Passo C, Criseo G. A multiplex PCR protocol for rapid identification of *Candida glabrata* and its phylogenetically related species *Candida nivariensis* and *Candida bracarensis*. *J Microbiol Methods.* 2009;79:117-20.
24. Esposto MC, Prigitano A, Romeo O, Criseo G, Trovato L, Tullio V, et al. Looking for *Candida nivariensis* and *C. bracarensis* among a large Italian collection of *C. glabrata* isolates: results of the FIMUA working group. *Mycoses.* 2013;56:394-6.
25. Treviño-Rangel RJ, Espinosa-Pérez JF, Villanueva-Lozano H, Montoya AM, Andrade A, Bonifaz A, et al. First report of *Candida bracarensis* in Mexico: hydrolytic enzymes and antifungal susceptibility pattern. *Folia Microbiol (Praha).* 2018;63:517-23.
26. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows95/98/NT. *Nucleic Acids Symp Ser.* 1999;41:95-8.
27. Altschul S, Madden T, Schäffer A, Zhang J, Zhang Z, Miller W, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res.* 1997;25:3389-402.
28. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. *Mol Biol Evol.* 2013;30:2725-9.
29. Librado P, Rozas J. DnaSP v5: a software for comprehensive analysis of DNA polymorphism data. *Bioinformatics.* 2009;25:1451-2.
30. Rozas J, Gullaud M, Blandin G, Aguadé M. DNA variation at the *rp49* gene region of *Drosophila simulans*: evolutionary inferences from an unusual haplotype structure. *Genetics.* 2001;158:1147-55.
31. Mu Z, Yang X, Yuan H. Detection and identification of wild yeast in Koumiss. *Food Microbiol.* 2012;31:301-8.
32. Lockhart SR, Messer SA, Gherna M, Bishop JA, Merz WG, Pfaller MA, et al. Identification of *Candida nivariensis* and *Candida bracarensis* in a large global collection of *Candida glabrata* isolates: comparison to the literature. *J Clin Microbiol.* 2009;47:1216-7.
33. Cendejas-Bueno E, Gómez-López A, Mellado E, Rodríguez-Tudela JL, Cuenca-Estrella M. Identification of pathogenic rare yeast species in clinical samples: comparison between phenotypical and molecular methods. *J Clin Microbiol.* 2010;48:1895-9.
34. Cuenca-Estrella M, Gómez-López A, Isla G, Rodríguez D, Almirante B, Pahissa A, et al. Prevalence of *Candida bracarensis* and *Candida nivariensis* in a Spanish collection of yeasts: comparison of results from a reference centre and from a population-based surveillance study of candidemia. *Med Mycol.* 2011;49:525-9.
35. Li J, Shan Y, Fan S, Liu X. Prevalence of *Candida nivariensis* and *Candida bracarensis* in vulvovaginal candidiasis. *Mycopathologia.* 2014;178:279-83.
36. Hou X, Xiao M, Chen SC, Wang H, Yu SY, Fan X, et al. Identification and antifungal susceptibility profiles of *Candida nivariensis* and *Candida bracarensis* in a multi-center Chinese collection of yeasts. *Front Microbiol.* 2017;8:5.
37. Morales-López SE, Taverna CG, Bosco-Borgeat ME, Maldonado I, Vivot W, Szusz W, et al. *Candida glabrata* species complex prevalence and antifungal susceptibility testing in a culture collection: first description of *Candida nivariensis* in Argentina. *Mycopathologia.* 2016;181:871-8.
38. Małek M, Mrowiec P, Klesiewicz K, Skiba-Kurek I, Szczepa ski A, Białecka J, et al. Prevalence of human pathogens of the clade *Nakaseomyces* in a culture collection: the first report on *Candida bracarensis* in Poland. *Folia Microbiol (Praha).* 2019;64:307-12.

39. Aznar-Marin P, Galan-Sanchez F, Marin-Casanova P, García-Martos P, Rodríguez-Iglesias M. *Candida nivariensis* as a new emergent agent of vulvovaginal candidiasis: description of cases and review of published studies. *Mycopathologia*. 2016;181:445-9.
40. Papaemmanouil V, Georgogiannis N, Plega M, Lalaki J, Lydakis D, Dimitriou M, et al. Prevalence and susceptibility of *Saccharomyces cerevisiae* causing vaginitis in Greek women. *Anaerobe*. 2011;17:298-9.
41. Massonet C, Van Eldere J, Vanechoutte M, De Baere T, Verhaegen J, Lagrou K. Comparison of VITEK 2 with ITS2-fragment length polymorphism analysis for identification of yeast species. *J Clin Microbiol*. 2004;42:2209-11.
42. Lott TJ, Frade JP, Lockhart SR. Multilocus sequence type analysis reveals both clonality and recombination in populations of *Candida glabrata* bloodstream isolates from U.S. surveillance studies. *Eukariot Cell*. 2010; 9:619-25.
43. Klotz U, Schmidt D, Willinger B, Steinmann E, Buer J, Rath PM, et al. Echinocandin resistance and population structure of invasive *Candida glabrata* isolates from two university hospitals in Germany and Austria. *Mycoses*. 2016;59:312-8.